Johnson & Johnson Forecasted to Earn Q2 2017 Earnings of $1.75 Per Share (NYSE:JNJ)
Johnson & Johnson (NYSE:JNJ) – Stock analysts at Jefferies Group issued their Q2 2017 earnings estimates for Johnson & Johnson in a report issued on Friday. Jefferies Group analyst J. Holford anticipates that the company will post earnings per share of $1.75 for the quarter. Jefferies Group currently has a “Hold” rating and a $145.00 target price on the stock. Jefferies Group also issued estimates for Johnson & Johnson’s FY2021 earnings at $9.87 EPS.
Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Tuesday, April 18th. The company reported $1.83 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.77 by $0.06. The firm had revenue of $17.77 billion for the quarter, compared to the consensus estimate of $18.02 billion. Johnson & Johnson had a net margin of 22.87% and a return on equity of 26.50%. The business’s quarterly revenue was up 1.6% compared to the same quarter last year. During the same quarter last year, the firm posted $1.68 EPS. COPYRIGHT VIOLATION WARNING: This news story was first posted by American Banking News and is the sole property of of American Banking News. If you are viewing this news story on another domain, it was illegally stolen and reposted in violation of US and international copyright and trademark legislation. The correct version of this news story can be accessed at https://www.americanbankingnews.com/2017/07/17/johnson-johnson-forecasted-to-earn-q2-2017-earnings-of-1-75-per-share-nysejnj.html.
A number of other equities research analysts have also commented on the company. J P Morgan Chase & Co upgraded Johnson & Johnson from a “neutral” rating to an “overweight” rating and upped their target price for the company from $123.64 to $140.00 in a research report on Monday, May 15th. Vetr lowered Johnson & Johnson from a “buy” rating to a “hold” rating and set a $128.82 target price on the stock. in a research report on Monday, May 15th. BTIG Research reiterated a “hold” rating on shares of Johnson & Johnson in a research report on Wednesday, April 19th. Cowen and Company reiterated a “buy” rating and issued a $143.00 target price (up previously from $138.00) on shares of Johnson & Johnson in a research report on Friday, May 19th. Finally, Morgan Stanley reiterated an “equal weight” rating and issued a $135.00 target price (up previously from $130.00) on shares of Johnson & Johnson in a research report on Friday, May 19th. Eleven investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus price target of $133.65.
Shares of Johnson & Johnson (NYSE JNJ) opened at 132.60 on Monday. Johnson & Johnson has a one year low of $109.32 and a one year high of $137.00. The stock has a market cap of $357.20 billion, a P/E ratio of 22.29 and a beta of 0.78. The stock’s 50 day moving average is $130.42 and its 200-day moving average is $122.68.
Institutional investors have recently added to or reduced their stakes in the company. Lenox Wealth Advisors Inc. boosted its position in Johnson & Johnson by 0.7% in the first quarter. Lenox Wealth Advisors Inc. now owns 871 shares of the company’s stock worth $108,000 after buying an additional 6 shares in the last quarter. Thomas J. Herzfeld Advisors Inc. purchased a new position in shares of Johnson & Johnson during the fourth quarter worth approximately $117,000. Harel Insurance Investments & Financial Services Ltd. boosted its position in shares of Johnson & Johnson by 241.0% in the first quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,190 shares of the company’s stock worth $149,000 after buying an additional 841 shares during the period. Empirical Finance LLC purchased a new position in shares of Johnson & Johnson during the fourth quarter worth approximately $144,000. Finally, Ullmann Financial Group Inc. purchased a new position in shares of Johnson & Johnson during the first quarter worth approximately $186,000. Institutional investors and hedge funds own 66.01% of the company’s stock.
About Johnson & Johnson
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.